Iqymune (human immune globulin intravenous 10%) / LFB SA - LARVOL DELTA

Long-Term Purity Profile of IQYMUNE®: A Direct Result of Quality by Design (ICNMD 2026) - "The sustained, exceptional purity of IQYMUNE® over time is a direct result of its foundational Quality by Design development. This demonstrates that a systematic QbD approach successfully builds and maintains high, consistent product quality throughout a product's lifecycle."

In vitro comparison between different 10% intravenous immunoglobulin preparations (DGHO 2021) - "Material and Purity profile and biological characteristics of IqY mune® were compared to other marketed 10% IVIg (Privigen®, Octagam®, Gamunex®, and Kiovig®). Although different IVIg preparations essentially consist of polyclonal IgG, the different purification processes lead to variations in other characteristics. The IqYmune manufacturing process developed with a QbD approach has generated a 10% IVIg having a higher level of quality and enhanced safety profile while maintaining a high level of efficacy."

Preclinical • Hypotension

An international multicenter efficacy and safety study of IQYMUNE® in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: PRISM study. (PubMed, J Peripher Nerv Syst) - "These results demonstrate that IqYmune® is an effective and well-tolerated treatment in patients with CIDP."

Clinical • Journal • Hematological Disorders • Pain

IqYmune® is an effective maintenance treatment for multifocal motor neuropathy: a randomised, double-blind, multicenter cross-over non-inferiority study versus Kiovig® - The LIME Study. (PubMed, J Peripher Nerv Syst) - "No thromboembolic events nor hemolysis nor renal impairment were observed. In this first clinical trial comparing two IVIg brands for maintenance treatment of MMN, efficacy and tolerability of both brands were similar."

Clinical • Head-to-Head • Journal • Complement-mediated Rare Disorders • Gene Therapies • Hematological Disorders • Pain • Renal Disease